The study established a LADA prevalence of 5.1% among T2D patients and has shown the role of GAD autoantibody in the screening for LADA. The study calls for a well- designed larger longitudinal study to generate strong evidence on the association of risk factors and complications associated with the LADA (BMC Endocrine Disorders)
Diabetes News
Tag: lada
Latent Autoimmune Diabetes in Youth Shows Greater Autoimmunity than Latent Autoimmune Diabetes in Adults: Evidence from a Nationwide, Multicenter, Cross-sectional Study
A high prevalence of LADY exists in youth with T2D phenotype. Latent autoimmune diabetes forms a continuous age-related spectrum from LADY to LADA, in which LADY shows greater autoimmunity (Pediatric Diabetes)
Comparing the bone mineral density among male patients with latent autoimmune diabetes and classical type 1 and type 2 diabetes, and exploring risk factors for osteoporosis
Compared with male patients with T2DM, lower BMDs were observed in patients with LADA and T1DM. Low BMI, uric acid, C-peptide levels, and high osteocalcin levels are risk factors for developing low BMD in male patients with diabetes (Journal of Endocrinological Investigation)
Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation
Patients with classic T1DM presented more often with symptoms, lower BMI and higher number of autoantibodies, which may be related to a more aggressive autoimmune process. Patients with LADA developed more frequently microvascular complications for the same disease duration, namely diabetic nephropathy, and had more often metabolic syndrome (Diabetology & Metabolic Syndrome)
Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: a cross sectional study
This is the first study offering a comparative evaluation of cardiac autonomic neuropathy among LADA, type 1 and type 2 diabetes, showing a lower risk of cardiac autonomic neuropathy in LADA compared to type 2 diabetes and similar compared to type 1 diabetes. This disparity was not due to differences in age, metabolic control or cardiovascular risk factors (Diabetic Medicine)
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
General screening for LADA in newly diagnosed non–insulin-requiring diabetes and, importantly, that large randomized clinical trials are warranted (Diabetes Care)
Bone mineral density spectrum in individuals with type 1 diabetes, LADA , and type 2 diabetes
BMD values in T1D, LADA and T2D were in an increasing order of mention. Patients with autoimmune diabetes were more susceptible to osteoporosis. A lower C‐peptide level may be responsible for decreased BMD in individuals with autoimmune diabetes (Diabetes/Metabolism Research and Reviews)
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults
At diabetes onset, adults with latent autoimmune diabetes have a lower risk of microvascular complications followed by a later higher risk of complications than do adults with type 2 diabetes, secondary to worse glycaemic control (The Lancet Diabetes & Endocrinology)
Immunological and clinical characteristics of latent autoimmune diabetes in the elderly
Autoantibodies GADA and Znt8A may be useful markers in identifying a subgroup of older patients with a clinical presentation of diabetes which could be characterized as latent autoimmune diabetes in the elderly (Diabetes/Metabolism Research and Reviews)
Investigating optimal β‐cell‐preserving treatment in latent autoimmune diabetes in adults: Results from a 21‐month randomized trial
β‐cell function after intervention was similar in patients with insulin‐ and sitagliptin‐treated LADA, regardless of the strength of autoimmunity. Further, participants with low levels of GAD antibodies did not experience progressive deterioration of β‐cell function over a 21‐month period. Taken together, these findings could be useful for clinicians’ choices of treatment in people with LADA (Diabetes, Obesity and Metabolism)
Individuals Fulfilling Criteria for Type 2 Diabetes Rather Than LADA Display Transient Signs of Autoimmunity Preceding Diagnosis With Possible Clinical Implications: The HUNT Study
We demonstrate signs of transient, prediagnostic evidence of autoimmune activity in patients later diagnosed and classified as having type 2 diabetes. Compared with other participants with type 2 diabetes, this subgroup had earlier onset of diabetes and may have lower β-cell function with possible clinical implications (Diabetes Care)
Lower mortality and cardiovascular event rates in patients with latent autoimmune diabetes in adults (LADA) as compared with type 2 diabetes and insulin deficient diabetes
LADA seems to be associated with lower mortality and lower risk of cardiovascular events, compared with both T2D and IDD (Diabetes Research and Clinical Practice)
Relative contribution of type 1 and type 2 diabetes loci to the genetic etiology of adult-onset, non-insulin-requiring autoimmune diabetes
LADA is genetically closer to T1D than T2D, although the genetic load of T1D risk alleles is less than childhood-onset T1D, particularly at the major histocompatibility complex region, potentially accounting for the later disease onset. Our results show that the genetic spectrum of T1D extends into adult-onset diabetes, where it can clinically masquerade as T2D (BMC Medicine)
Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes
Persons with LADA express higher DPP-4 activity compared to persons with both type 1 and type 2 diabetes. The possible patophysiological role of DPP-4 in the LADA pathogenesis needs to be further evaluated (Diabetes Research and Clinical Practice)
Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9
The present study shows that the magnitude of stimulated insulin secretion in LADA is intermediate between that of type 1 and type 2 diabetes mellitus (BMC Endocrine Disorders)
Glycosmedia is also available as an App: